Article
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jun 2013
Chen G, Feng J, Zhou C, Wu Y-L, Liu X-Q, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C-P, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C
Abstract excerpt
BACKGROUND: The OPTIMAL study found that erlotinib improved progression-free survival (PFS) versus standard chemotherapy in Chinese patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). This report describes the quality of life (QoL) and updated PFS analyses from this study. PATIENTS AND METHODS: Chinese patients ≥ 18 years with histologically confirmed stage IIIB or IV NSCLC and a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.